Cytokinetics

(CYTK) - Get Report

said its experimental head-and-neck cancer drug ispinesib failed a clinical trial in which it was meant to reduce or eliminate tumors. Cytokinetics shares were losing 14 cents, or 2.2%, to $6.21.

Allos Therapeutics

( ALTH) rose after the company said the Food and Drug Administration granted its lymphoma drug PDX fast-track review status. The stock was up 4% to $3.89.

Baxter International

(BAX) - Get Report

is selling its transfusion business for $540 million to a group that includes private equity firm Texas Pacific. Shares of Baxter were up 6 cents at $45.24.

Heart-device makers' stocks were mixed after Merrill Lynch medical technology analyst Katherine Owen issued a number of ratings changes. The analyst downgraded

Abbott

(ABT) - Get Report

to neutral and

Boston Scientific

(BSX) - Get Report

to sell. She reiterated her buy rating on

Johnson & Johnson

(JNJ) - Get Report

.

St. Jude Medical

(STJ)

, which separately announced that its chronic-pain neurostimulation system received regulatory and reimbursement approval in Australia, was upgraded to buy. Abbott's shares lost 1.3% to $47.61, Boston Scientific was 1.2% lower, trading at $14.50, St. Jude's stock gained 3% to $36.45, and J&J's shares were up 0.3% to $65.29.

Other health stocks on the move included

Amgen

(AMGN) - Get Report

, 1.4% higher to $71.26,

Elan

(ELN)

, up 1.5% to $15.45,

MGI Pharma

( MOGN) gaining 2.5% to $17.36,

Meridian Bioscience

(VIVO) - Get Report

rising 4.9% to $23.59,

SkyePharma

( SKYE), whose shares were boosted 10.4% to $5, and

ViaCell

( VIAC), up 4.5% to $4.55.

Barr Pharmaceuticals

( BRL) lost 1.5% to $51.37,

Novogen

(NVGN)

traded 5.8% lower to $10.37,

BioCryst Pharmaceuticals

(BCRX) - Get Report

fell 4.1% to $11.11,

Valera Pharmaceuticals

(VLRX) - Get Report

lost 6.1% to $6.30, and

Dyadic International

( DIL) shares were off 6.5% to $3.73.